Sfta2 Inhibitors
Chemical inhibitors of Sfta2 function through various molecular mechanisms to inhibit the activity of specific kinases and signaling pathways. Erlotinib and lapatinib are both inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is known to play a significant role in the regulation of lung epithelium. Inhibition of EGFR by these compounds can reduce the activity of Sfta2 by diminishing the cellular proliferation signals that are mediated through this pathway. Gefitinib similarly targets EGFR tyrosine kinase and by doing so, it can suppress the activity of Sfta2 by interfering with the lung epithelial cell regulation. Vandetanib extends this inhibitory effect by also targeting the tyrosine kinases of VEGFR and RET, which can lead to a decrease in angiogenesis and cellular proliferation where Sfta2 is involved.
Sorafenib and sunitinib are multi-targeted receptor tyrosine kinase inhibitors. Sorafenib targets VEGFR, PDGFR, and Raf kinases, while sunitinib targets VEGFR, PDGFR, and KIT. The inhibition of these kinases can reduce the signaling pathways that are crucial for the activity of Sfta2, leading to functional inhibition of the protein's role in cellular processes. Axitinib and pazopanib also inhibit multiple tyrosine kinases, including VEGFR and PDGFR, further contributing to the reduction of signaling pathways that are important for the functional involvement of Sfta2 in various pathological states. Dasatinib, which targets BCR-ABL and SRC family kinases, and bosutinib, which targets SRC and ABL kinases, can disrupt downstream signaling pathways that are essential for the role of Sfta2, thereby inhibiting its function in the cellular processes. Nilotinib, a selective BCR-ABL tyrosine kinase inhibitor, can also reduce the activity of Sfta2 by inhibiting signaling pathways in lung tissue. Lastly, crizotinib targets ALK and ROS1 tyrosine kinases, and its inhibition can lead to a reduction in the activity of Sfta2, particularly in lung pathology signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Since Sfta2 is implicated in pulmonary diseases and EGFR signaling is involved in lung epithelium regulation, erlotinib inhibition of EGFR could reduce Sfta2-related pathological processes by diminishing EGFR-mediated cellular proliferation. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is another EGFR tyrosine kinase inhibitor which also targets HER2/neu. By inhibiting EGFR, lapatinib could reduce the signaling cascades that may involve Sfta2 in lung epithelial cells, leading to a decrease in Sfta2 activity related to cell proliferation and survival. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib targets multiple tyrosine protein kinases such as VEGFR and PDGFR, and also Raf kinases. By inhibiting these kinases, sorafenib could interfere with signaling pathways that might be crucial for Sfta2's role in cells, potentially inhibiting Sfta2's functional contribution to pathological states. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor, including for VEGFR, PDGFR, and KIT. Inhibition of these kinases can lead to a reduction in signaling pathways that Sfta2 may participate in within the lung tissue, therefore functionally inhibiting Sfta2's involvement in disease processes. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an inhibitor of EGFR tyrosine kinase, and by inhibiting EGFR, gefitinib could suppress the signaling pathways that involve Sfta2 in lung epithelial cell regulation, thus inhibiting the functional activity of Sfta2 in disease. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib selectively inhibits the tyrosine kinases of VEGFR, EGFR, and RET. By inhibiting these, vandetanib could curtail the signaling mechanisms that Sfta2 may be involved in, particularly in angiogenesis and cellular proliferation, leading to functional inhibition. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor with activity against BCR-ABL and SRC family kinases. By inhibiting SRC kinases, dasatinib could disrupt downstream signaling pathways where Sfta2 might play a role, thereby inhibiting its function in cellular processes. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Pazopanib inhibits multiple tyrosine kinases, including VEGFR, PDGFR, and KIT. Its inhibition of these pathways can interfere with signaling processes that involve Sfta2, leading to a potential functional inhibition of Sfta2's role in disease states. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Nilotinib is a selective BCR-ABL tyrosine kinase inhibitor. While primarily used in leukemia, its inhibition of tyrosine kinases might also reduce Sfta2-related signaling in lung tissue, offering a functional inhibition of Sfta2's role in pathological processes. | ||||||